Loading clinical trials...
Loading clinical trials...
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Synta Pharmaceuticals Corp.
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05533697 · Advanced Solid Tumors
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
NCT07019779 · Advanced Solid Tumors
NCT06922357 · Advanced/Metastatic Solid Tumors
UCLA
Los Angeles, California
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions